SYNC-T® Personalized In Situ Combination Immunotherapy

Charles J. Link, M.D.

Adjunct Professor, Lankenau Institute for Medical Research

Co-Founder & Executive Chairman, Syncromune, Inc.

Legal Information & Disclaimer

This presentation includes forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained in this presentation or expressed orally in connection herewith that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, forward-looking statements can be identified by phrases such as "plans," "intends," "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Accordingly, you should not place undue reliance on our forward-looking statements. The forward-looking statements contained in this presentation or expressed orally in connection herewith are made only as of the date of this presentation and we undertake no obligation to update the forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.

None of Syncromune, Inc., its affiliates or their respective directors, officers, employees or agents gives any representation or warranty, express or implied, as to: (i) the achievement or reasonableness of future projections, management targets, estimates or prospects contained in this presentation; or (ii) the accuracy or completeness of any information contained in this presentation, any other written information or oral information provided in connection herewith or any data that any of them generates.

This presentation was prepared by us for informational purposes only and does not constitute an offer, or solicitation of an offer, to sell any securities at any time. None of Syncromune's securities have been registered under the Securities Act of 1933, as amended, or any state securities law. Such securities have not been approved or disapproved by the Securities and Exchange Commission or by any state securities regulatory authority, nor has the Securities and Exchange Commission or any such state authority passed on the accuracy or adequacy of this presentation. Any representation to the contrary is a criminal offense.

Some of the information contained in this presentation may be derived from information provided by industry sources. We believe that such information is accurate and that the sources from which it has been obtained are reliable; however, we cannot guarantee the accuracy of such information and have not independently verified such information.

All patients admitted to our trials have signed an informed consent in accordance with the WMA Declaration of Helsinki involving ethical principles for medical research involving human subjects.

Syncromune is Developing Novel Combination Immunotherapies

Headquarters

Fort Lauderdale, FL

Employees

32

Financing

Pursuing Series A

Therapeutic Area

Metastatic Solid Tumor Cancers

Thinking Outside the Box to Address Current Treatment Limitations

The Problem

Low Response Rates in Solid Tumor Cancers

Only 15-20% of patients with metastatic solid tumor cancers respond to current systemic IV immunotherapy

Current Immunotherapies Not Effective in mCRPC

mCRPC is especially treatment resistant, with **overall response rates of 3-5%** when treated with systemic IV immunotherapy

High Rate of Autoimmune Side Effects with Combos

Combination IV immunotherapy has demonstrated slightly improved outcomes, but it's potential is limited due to systemic autoimmune side effects

Our Solution

SYNC-T, a new combination approach that simultaneously targets multiple mechanisms of cancer immune suppression

- In situ vaccine creation
- Multi-target biologic drug
- Drug infusion directly into tumor
- High concentration, low dose

mCRPC = metastatic castration-resistant prostate cancer

SYNC-T Uses a Combination Approach to Overcome Treatment Resistance

Partial oncolysis of target tumor

Infusion of multi-target biologic

T cell activation



- This combination approach is designed to empower the immune system to **create systemic anti-tumor immunity**
- Initial candidate is SYNC-T SV-102 for metastatic castration-resistant prostate cancer (mCRPC) which has demonstrated poor responses to current systemic IV immunotherapies

Compelling Interim Phase 1 Data for mCRPC Demonstrated 85% ORR

Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Best Response in Evaluable Subjects (n=13)	
Overall Response Rate	84.6%
Stable Disease	15.4%
Partial Response	46.1%
Complete Response	38.5%
Complete Resolution of Bone Metastases	53.8%
Progressive Disease	0%

- 85% Overall Response Rate (ORR)
- 46% Partial Response (PR)
- **38% Complete Response (CR)**

NCT05544227 – Data presented as of 9 Mar 2024; all patients enrolled by 10 Jan 2024. Total N = 15 patients

Subject SV-102-09: Complete Response

- Subject was confirmed via RECIST as a Complete Response
- Tumor was PD-1/ PD-L1 NEG and proficient MMR
- Complete resolution of >50 bone metastases



PRE-THERAPY. 5/2023 coronal PSMA PET/CT shows extensive bone metastases (greater than 50)



POST-THERAPY. 12/2023 coronal PSMA PET/CT shows complete resolution of all bone metastases



PRE-THERAPY. 5/2023 sagittal PSMA PET/CT shows extensive bone metastases



POST-THERAPY. 12/2023 sagittal PSMA PET/CT shows complete resolution of all bone metastases

Favorable Safety Profile

- Majority Grade 1 or 2 immune-related adverse events
- Flu-like symptoms that quickly resolved and easy to manage
- No Grade 3 or 4 autoimmune toxicities
- How SYNC-T is different:
  - ✓ **Has demonstrated the potential to effectively combine multiple immunotherapies while avoiding major systemic autoimmune side effects**

Addressing a Large Unmet Need in mCRPC and Other Solid Tumors

Currently no known cure for mCRPC

299,010

New cases of prostate cancer in the U.S. in 2024

35,250

Estimated deaths from prostate cancer in the U.S. in 2024

Multi-billion-dollar markets in both the U.S. and ROW

Broad platform with potential to target virtually all solid tumor cancers

LEGION-100 Phase 2a Trial for mCRPC Enrollment Initiated

Building upon strong data from Phase 1 mCRPC

SYNC-T SV-102 for metastatic castration-resistant prostate cancer

Part 1: Dose Escalation 3 x 3 rule up to 18 patients

Initial site is Lankenau Institute for Medical Research (LIMR) in the greater Philadelphia area

Part 2: Dose Optimization w/ 40 patients total randomized into 2 cohorts

Multiple sites to be activated to support rapid enrollment

Investment Highlights

Lead candidate SV-102 targeting mCRPC demonstrated 85% ORR in Phase 1 mCRPC

Unprecedented Phase 1 Interim Data	▪ Interim data for mCRPC demonstrated high response rate with low adverse events ▪ **38% complete response (CR) and 46% partial response (PR)**
Novel Combination Immunotherapy	▪ New approach: combination partial oncolysis & multi-target biologic for mCRPC ▪ **Addressing unmet needs in multi-billion-dollar market for incurable mCRPC**
Phase 2a Enrollment Initiated	▪ **LEGION-100 Phase 2a trial for mCRPC enrollment initiated** ▪ Clinical development plan optimized for rapid enrollment

syncromune

Thank You

Charles Link, M.D.

clink@syncromune.com

www.syncromune.com

PIPER | SANDLER